Karuna Therapeutics surges 47% after Bristol Myers Squibb announces $14 billion deal
In a strategic move, Bristol Myers Squibb has announced its acquisition of biopharmaceutical company Karuna Therapeutics for a substantial $14 billion in cash, equivalent to $330 per share. This development … Read More